United States Intervenes in Genentech Constitutional Challenge


We have covered Pfizer’s development of biosimilars of Genentech’s Avastin® (bevacizumab) and Herceptin® (trastuzumab) and its related IPR filings IPR2016-01771 and IPR2016-01837. Following written decisions invalidating those two patents, Genentech appealed and challenged the constitutionality of subjecting patents that issued before the America Invents Act (AIA) was enacted in 2011 to inter partes review. The Federal Circuit had certified Genentech’s constitutional challenges to the U.S. Attorney General and directed the Attorney General to inform the Court whether the United States intended to intervene in the appeals. In unopposed motions to intervene, (here and here), the Attorney General moved to “exercise its statutory right to intervene in this appeal under 28 U.S.C. § 2403(a) to defend the constitutionality of the Act of Congress that appellant challenges.” The Federal Circuit granted the motions (here and here) and ordered the appellee and the United States to provide responsive briefs by November 5, 2018.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.